PRODUCTS & SERVICES
The Economist's 8th Annual World Cancer Series: Europe conveyed a wide range of stakeholders critical to effective cancer care to drive innovation, equity, and excellence in cancer control across Europe.
This year’s conference focused on innovation, equity, and excellence: interesting agenda, great speakers, and fruitful meetings with innovative leaders across the fields.
In the critical time ahead, collaboration and knowledge sharing on the mission hunt for innovative and efficient solutions are crucial for future cancer diagnostics and patient treatments. Without conclusive action, by 2035 cancer cases are estimated to increase by almost 25%, making it the leading cause of death in the EU.
For more info, click here.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.